diagnostics

Danaher Corporation approved a $0.40 per share quarterly dividend payable July 31, 2026, demonstrating ongoing shareholder return commitment.

IDEXX Laboratories beats Q1 expectations and raises full-year guidance, citing stronger clinical visits and diagnostic frequency across its pet healthcare segment.

Roche offers defensive 2026 portfolio appeal with 7% sales growth and 13% profit growth, emphasizing stability over explosive expansion through diversified healthcare exposure.

Labcorp ($LH) shares rise 1.46% after beating Q1 earnings expectations with $4.25 adjusted EPS and raising full-year 2026 guidance, bolstered by AI and robotics investments.

Danaher trades 31% below historical valuation after 36% decline, but Masimo acquisition and resumed growth suggest recovery is underway for the storied life sciences leader.

Roche and NVIDIA expand AI infrastructure with 2,176 on-premises GPUs across U.S. and Europe, totaling 3,500 Blackwell units to accelerate drug discovery and diagnostics.

Agilent acquires Biocare Medical for $950M to expand pathology and immunohistochemistry capabilities. Deal expected accretive to EPS within 12 months, closing by Q4 2026.

Trinity Biotech received a Nasdaq non-compliance notice for failing to maintain minimum share value requirements. The company has 180 days to restore compliance or face delisting.

Danaher acquires Masimo for $9.9 billion in cash, expanding its medical technology portfolio with expected synergies exceeding $175 million annually.

Trinity Biotech received a Nasdaq delisting warning after failing to maintain the $1.00 minimum bid price. The company has until August 2026 to restore compliance or face delisting.